Health Care [ 3/12 ] | Biotechnology [ 26/74 ]
NASDAQ | Common Stock
Janux Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer.
The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.
Its development pipeline also consists of discovery stage products.
The company has strategic research collaboration agreement with Merck Sharp & Dohme Corp. to develop TRACTr product candidates.
Janux Therapeutics, Inc. was incorporated in 2017 and is headquartered in San Diego, California.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Nov 7, 24 | -0.51 Decreased by -104.00% | -0.36 Decreased by -42.98% |
| Aug 6, 24 | -0.11 Increased by +73.81% | -0.31 Increased by +64.52% |
| May 7, 24 | -0.30 Increased by +28.57% | -0.33 Increased by +9.09% |
| Mar 8, 24 | -0.25 Increased by +35.90% | -0.41 Increased by +39.02% |
| Nov 7, 23 | -0.25 Increased by +37.50% | -0.47 Increased by +46.81% |
| Aug 8, 23 | -0.42 Decreased by -2.44% | -0.52 Increased by +19.23% |
| May 9, 23 | -0.42 Decreased by -31.25% | -0.49 Increased by +14.29% |
| Mar 10, 23 | -0.39 Decreased by -18.18% | -0.49 Increased by +20.41% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 439.00 K Decreased by -82.56% | -28.06 M Decreased by -142.56% | Decreased by -6.39 K% Decreased by -1.29 K% |
| Jun 30, 24 | 8.90 M Increased by +741.72% | -5.96 M Increased by +65.96% | Decreased by -66.98% Increased by +95.96% |
| Mar 31, 24 | 1.25 M Decreased by -38.87% | -14.76 M Increased by +15.46% | Decreased by -1.18 K% Decreased by -38.29% |
| Dec 31, 23 | 2.46 M Decreased by -13.50% | -11.76 M Decreased by -4.42% | Decreased by -477.77% Decreased by -20.72% |
| Sep 30, 23 | 2.52 M Increased by +38.83% | -11.57 M Increased by +17.63% | Decreased by -459.59% Increased by +40.67% |
| Jun 30, 23 | 1.06 M Decreased by -55.31% | -17.51 M Decreased by -6.01% | Decreased by -1.66 K% Decreased by -137.20% |
| Mar 31, 23 | 2.05 M Increased by +28.89% | -17.46 M Decreased by -32.81% | Decreased by -852.49% Decreased by -3.04% |
| Dec 31, 22 | 2.85 M Increased by +76.05% | -11.26 M Increased by +16.07% | Decreased by -395.78% Increased by +52.33% |